MiNK Therapeutics, Inc. Accounts Payable
MiNK Therapeutics, Inc. (INKT) had Accounts Payable of $3.92 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-13
- 2026-06-30: Accounts Payable, Current $3.92M.
- 2026-03-31: Accounts Payable, Current $3.39M.
- 2025-12-31: Accounts Payable, Current $3.43M.
- 2025-09-30: Accounts Payable, Current $3.69M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $3.92M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.39M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $3.43M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $3.69M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $3.31M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $2.66M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $2.73M 10-K · filed 2026-03-31 |
| 2024-09-30 | $2.36M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.20M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $3.49M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $3.91M 10-K · filed 2025-03-18 |
| 2023-09-30 | $4.28M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $4.89M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $6.00M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $5.82M 10-K · filed 2024-03-21 |
| 2022-09-30 | $5.17M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $4.79M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $3.73M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $3.00M 10-K · filed 2023-03-24 |
| 2021-09-30 | $1.65M 10-Q · filed 2021-11-29 |
| 2020-12-31 | $3.14M 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |